Relief Therapeutics $RLFTF 2022 Prospects
The small Swiss biotech company has a product pipeline and partnerships that mean it will soon graduate from the OTC markets.
One of its partners, NeuroRx, agreed in December to a merger with blank-check company Big Rock. $BRPA’s stock price has been very volatile since it also includes Relief Therapeutics’ covid-19 therapy which could not only save lives but protect against lung damage.
For those of you in Switzerland and Germany, please share this article on LinkedIn here.
The Top Covid-19 Penny Stock of the Second Half of 2021 and 2022
Currently $RLFTF is just an obscure OTC stock at barely $0.20. However when it gets listed, it will be introduced to Robinhood users among others. To this end they are also improving their management and leadership team. They recently appointed Taneli Jouhikainen, M.D., MBA, to the newly created position of Chief Operating Officer (COO), effective June 1, 2021.
With the U.S. barely even having a 50% vaccination rate, there are too many anti-vaxxers for this to be the end of the pandemic, given that B.1.617.2 is trending in the UK, and new combinations of B117 and B.1.617 are popping up in Asia. This means the fall 2021 wave will spread much faster among non-vaccinated populations including western countries that don’t have satisfactory opt-in levels to vaccines due to Russian misinformation campaigns.
Our Highest Rated OTC BioTech Stock
Relief Therapeutics has a lead compound called RLF-100TM (aviptadil) that is in advanced clinical development to treat COVID-19 induced respiratory disorders and could become important in the next wave for North America and Europe. So while the stock is currently around $0.23, it could soon be well over $1.00.
Relief for its size has above average pipeline diversification and partnerships. Relief’s lead drug candidate RLF-100TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19 and has shown promising results.
Having met the primary endpoints in the trials, the effort will now be seeking emergency-use authorization from the U.S. Food and Drug Administration. Relief doesn’t do PR well, and this makes it a bargain price below $0.25. However the efficacy of the treatment on the front lines could be superb.
As the fate of the Swiss company’s stock seems tied up in its partnership with soon-to-be BRPA-owned NeuroRx, investor interest is shifting from vaccine developers to treatment makers and therapeutics firms. If you thought the Covid-19 pandemic was over, you are gravely mistaken.
Relief also has a partnership with Acer that is quite interesting. The volatility in BRPA shows how trending Relief could become when it graduates out of the OTC spectrum of stocks. It has a 52-week range of $0.01 to $0.95. With OTC stock seasonal strongly favoring the June to January part of the year, the fall wave of 2021 could see this stock get more attention.
Good Timing Is Everything
The company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. After careful analysis the Last Futurist has a high conviction rate on this business and their progress looks good in 2021. Always do your own due diligence.
Therapeutics Holding AG is based in Geneva, Switzerland. They are also in a phase 2 trial evaluating the inhaled formulation of RLF-100 for the prevention of COVID-19-related acute respiratory distress syndrome (“ARDS”) in association with German based AdVita. The company’s ability to form partnerships in Europe and abroad is relatively high.
However their lead candidate is good enough to be used in ICUs globally. With the newer faster onset of Covid-19 to mortality (like we are seeing in some cases in Taiwan, for example) it means this treatment could become more important on the front lines against faster transmitting variants.
Given all the data, the relative obscurity of the stock and the prospects of more transmissible variants, namely B.1.617.2 and its sub-variants, $RLFTF has a buy rating and has good prospects in 2022. The best treatments to protect our lungs will be immeasurably valuable.
Some patients don’t even realize they are experiencing lung damage with the faster transmissible variants. The faster onset and quicker transmission will realistically be more difficult to contain. In the U.K. this variant is replacing the Kent variant as the dominant strain, even in a country with a high first dose vaccination rate.
OTC stocks are among the most volatile of the micro cap stocks and once they gain compliance can go from vastly under $1 to $3 or even $5 relatively quickly. Not all brokers allow the purchase of OTC stocks. In some cases when the product could have such a high impact on the real world, it’s worth getting into early.
The downward pressure on the OTC market has been extreme since its high in February 2021 and this stock could continue to go down in this summer. However in 2022 it could see a much higher spike. Therefore this is a long-term investment on the thesis that its covid-19 solution will go global, which will take some time.